Impaired glucose tolerance: Do pharmacological therapies correct the underlying metabolic disturbance?

Ralph A. DeFronzo

doi:10.1177/1474651403003001s0601

Impaired glucose tolerance: Do pharmacological therapies correct the underlying metabolic disturbance?

Ralph A. DeFronzo

Medicine

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Lifestyle intervention prevents or delays the conversion from impaired glucose tolerance (IGT) to type 2 diabetes. However, many subjects fail to achieve and/or maintain long-term weight loss and to follow a regular exercise regimen may require pharmacologic therapy. Insulin resistance in liver, muscle and fat, along with impaired beta-cell function, plays a central role in the pathogenesis of type 2 diabetes. Insulin sensitising drugs, including metformin and the thiazolidinediones, have significantly reduced the conversion rate of IGT to type 2 diabetes in subjects in several large, well designed clinical trials. Insulin-sensitising drugs are likely to play an important role in future strategies for diabetes prevention.

Original language	English (US)
Pages (from-to)	S24-S40
Journal	British Journal of Diabetes and Vascular Disease
Volume	3
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1177/1474651403003001s0601
State	Published - Jan 1 2003

Keywords

Beta-cell dysfunction
Impaired glucose tolerance
Insulin resistance
Metformin
Thiazolidinediones
Type 2 diabetes

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Cardiology and Cardiovascular Medicine

Access to Document

10.1177/1474651403003001s0601

Fingerprint Dive into the research topics of 'Impaired glucose tolerance: Do pharmacological therapies correct the underlying metabolic disturbance?'. Together they form a unique fingerprint.

Cite this

@article{ef2c61f1cd01481eaf78a03d9cc8ddc0,

title = "Impaired glucose tolerance: Do pharmacological therapies correct the underlying metabolic disturbance?",

abstract = "Lifestyle intervention prevents or delays the conversion from impaired glucose tolerance (IGT) to type 2 diabetes. However, many subjects fail to achieve and/or maintain long-term weight loss and to follow a regular exercise regimen may require pharmacologic therapy. Insulin resistance in liver, muscle and fat, along with impaired beta-cell function, plays a central role in the pathogenesis of type 2 diabetes. Insulin sensitising drugs, including metformin and the thiazolidinediones, have significantly reduced the conversion rate of IGT to type 2 diabetes in subjects in several large, well designed clinical trials. Insulin-sensitising drugs are likely to play an important role in future strategies for diabetes prevention.",

keywords = "Beta-cell dysfunction, Impaired glucose tolerance, Insulin resistance, Metformin, Thiazolidinediones, Type 2 diabetes",

author = "DeFronzo, {Ralph A.}",

year = "2003",

month = jan,

day = "1",

doi = "10.1177/1474651403003001s0601",

language = "English (US)",

volume = "3",

pages = "S24--S40",

journal = "British Journal of Diabetes and Vascular Disease",

issn = "1474-6514",

publisher = "SAGE Publications Inc.",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Impaired glucose tolerance

T2 - Do pharmacological therapies correct the underlying metabolic disturbance?

AU - DeFronzo, Ralph A.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Lifestyle intervention prevents or delays the conversion from impaired glucose tolerance (IGT) to type 2 diabetes. However, many subjects fail to achieve and/or maintain long-term weight loss and to follow a regular exercise regimen may require pharmacologic therapy. Insulin resistance in liver, muscle and fat, along with impaired beta-cell function, plays a central role in the pathogenesis of type 2 diabetes. Insulin sensitising drugs, including metformin and the thiazolidinediones, have significantly reduced the conversion rate of IGT to type 2 diabetes in subjects in several large, well designed clinical trials. Insulin-sensitising drugs are likely to play an important role in future strategies for diabetes prevention.

AB - Lifestyle intervention prevents or delays the conversion from impaired glucose tolerance (IGT) to type 2 diabetes. However, many subjects fail to achieve and/or maintain long-term weight loss and to follow a regular exercise regimen may require pharmacologic therapy. Insulin resistance in liver, muscle and fat, along with impaired beta-cell function, plays a central role in the pathogenesis of type 2 diabetes. Insulin sensitising drugs, including metformin and the thiazolidinediones, have significantly reduced the conversion rate of IGT to type 2 diabetes in subjects in several large, well designed clinical trials. Insulin-sensitising drugs are likely to play an important role in future strategies for diabetes prevention.

KW - Beta-cell dysfunction

KW - Impaired glucose tolerance

KW - Insulin resistance

KW - Metformin

KW - Thiazolidinediones

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=0038574723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038574723&partnerID=8YFLogxK

U2 - 10.1177/1474651403003001s0601

DO - 10.1177/1474651403003001s0601

M3 - Review article

AN - SCOPUS:0038574723

VL - 3

SP - S24-S40

JO - British Journal of Diabetes and Vascular Disease

JF - British Journal of Diabetes and Vascular Disease

SN - 1474-6514

IS - SUPPL. 1

ER -